DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) progression is a major clinical challenge.
• Understanding HCC molecular mechanisms is crucial for effective therapies.
• The role of Dumbbell former 4 (DBF4)-dependent kinase (DDK) in HCC is largely unknown.

Purpose of the Study:

• To investigate the role of DBF4 in HCC progression.
• To elucidate the molecular mechanisms by which DBF4 affects HCC.
• To evaluate DDK inhibition combined with immunotherapy for HCC treatment.

Main Methods:

• Analysis of DBF4 expression in HCC tissues.
• Identification of upstream regulators and downstream targets of DBF4.
• In vitro and in vivo experiments to assess DBF4's impact on HCC.
• Combination therapy studies using DDK inhibitor XL413 and anti-PD-1 immunotherapy.

Main Results:

• DBF4 expression is upregulated in HCC and predicts poor patient survival.
• p65 upregulates DBF4 expression by binding to its promoter.
• DBF4 accelerates HCC cell proliferation and tumorigenesis.
• DBF4-CDC7 complex activates STAT3 signaling via XPO1-mediated nuclear export.
• p65 enhances DDK nuclear transport and DDK-STAT3 interaction by upregulating XPO1.
• DBF4 expression correlates with activated STAT3 and XPO1 in HCC tissues.
• Combination of XL413 and anti-PD-1 immunotherapy suppressed HCC growth and prolonged survival in mice.

Conclusions:

• DBF4-dependent kinase (DDK) promotes HCC progression by activating the STAT3 pathway.
• Targeting DDK can enhance the efficacy of anti-PD-1 immunotherapy in HCC.
• This study provides a proof-of-concept for DDK-targeted therapy in HCC.